Dr. Ben Davies received his PhD in molecular biology from the University of Edinburgh where he first encountered gene targeting techniques at the Centre for Genome Research. After a postdoc at the Charite Hospital Berlin, he moved into commercial biotech working as scientific director for a start-up transgenic service company based at the University Hospital Hamburg-Eppendorf which was then merged with the French Biotech company, Genoway. After 4 years in this role, he moved to Oxford where he runs the transgenic core research group at the Wellcome Centre for Human Genetics at the University of Oxford, a position he has held for the last 12 years.
Ben Davies, University of Oxford
